A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer

BACKGROUND: Programmed cell death-1 (PD-1) immune checkpoint inhibitor antibody has proven to be effective in advanced non-small cell lung cancer (NSCLC) patients positive for programmed cell death-1 ligand-1 (PD-L1). However, there are currently no prospective studies evaluating PD-L1 expression fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsunoda, Akihito, Morikawa, Kei, Inoue, Takeo, Miyazawa, Teruomi, Hoshikawa, Masahiro, Takagi, Masayuki, Mineshita, Masamichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555021/
https://www.ncbi.nlm.nih.gov/pubmed/31174496
http://dx.doi.org/10.1186/s12885-019-5773-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555021/
https://www.ncbi.nlm.nih.gov/pubmed/31174496
http://dx.doi.org/10.1186/s12885-019-5773-3

Ejemplares similares